FDA Peptide Notice: 6 White House Meetings, No Text Yet

Summary. As of 24 October 2026, the White House Office of Information and Regulatory Affairs (OIRA) still lists the FDA notice "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94) as pending review, as it has since it was received on 14 October. OIRA's public meeting log for the notice now shows six meetings with outside parties, scheduled between 21 and 28 October, compared with the single meeting listed when this review was first covered here on 19 October. These six meetings are unrelated to the six peptides the advisory committee recommended in July; no published FDA notice lists six peptides. The text of the notice has not been published.

Research context (RUO). According to the reginfo.gov meeting records, the requesters are the American Academy of Peptide Medicine (21 October), Hims & Hers Health (23 October), the Alliance for Pharmacy Compounding and the Center for Science in the Public Interest (both 27 October), and, on 28 October, Faegre Drinker Consulting for its client the Collaborative for Evidence-Based Medicines and Carmen Group for its client Medivant Healthcare. The records show who asked to meet and when, not what was discussed. Reuters reported on 15 October that the filing gives no details of the policy, that FDA advisers had recommended in July loosening restrictions on six of seven peptides under review (an advisory recommendation, not an FDA notice), and that the peptides under consideration have not been approved by FDA as safe or effective. OIRA's FAQ states that draft documents under review are deliberative and not released during review, and that Executive Order 12866 limits review to 90 days, with no minimum and with possible extensions. For context, FDA's page on Section 503A of the FD&C Act explains the framework such a notice would sit in: state-licensed pharmacists and physicians may compound only from bulk drug substances that have an applicable USP or NF monograph, are components of an FDA-approved drug, or appear on the 503A bulks list, and each bulk substance must be accompanied by a valid certificate of analysis and made by an FDA-registered establishment. The same page describes an existing interim policy that sets out conditions under which FDA does not intend to take action while nominated substances are evaluated, which is an enforcement policy rather than an approval. Until a text is published, the notice's scope, the substances it covers and any conditions remain unknown.

Related: FDA Peptide Compounding Policy Tracker 2026, a sourced status page for the interim notice, the July advisory votes and the 503A bulks list.

This summary is for research-community awareness only and is not legal advice.